Grace Therapeutics, Inc. (GRCE) stock
Close on Nov 11, 2026Market cap $39.02MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $39.02M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.81
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$20.22M
- EPS, diluted
- -$1.18
- Book value per share
- $2.79
- Diluted shares
- 17M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $1.86
- Open
- $1.86
- Day's range
- $1.81 – $1.90
- Volume
- 8,844
- Average volume (20 days)
- 119,104
- Beta (5 years)
- 0.95
- 52-week range
- $1.67 – $5.18
- RSI (14 days)
- 44.2
- Volatility (1 year)
- 72.0%
- Relative volume
- 0.06×
- WACC
- 9.6%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | GRCE | S&P 500 | Difference | GRCE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.8% | -2.4% | −8.4 pts | ||
| 3 months | -12.5% | -1.2% | −11.3 pts | ||
| Year to date | -46.4% | +12.3% | −58.7 pts | ||
| 1 year | -38.2% | +12.4% | −50.6 pts | ||
| 3 years | -16.6% | +78.8% | −95.4 pts | -5.9% | +21.4% |
| 5 years | -81.0% | +75.2% | −156.2 pts | -28.3% | +11.9% |
| 10 years | -97.2% | +311.1% | −408.3 pts | -30.1% | +15.2% |
Ten years at a glance
Fiscal years 2016 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Grace Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- News
- News
- Results
About Grace Therapeutics
Pharmaceutical Preparations
Grace Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. The company uses proprietary drug delivery and formulation technologies to reformulate existing pharmaceutical compounds into treatments with improved clinical outcomes, faster onset, reduced side effects, and enhanced patient compliance. Its clinical pipeline consists of three candidate products: lead candidate GTx-104, an intravenous injectable formulation of nimodipine; GTx-102, evaluated for pediatric ataxia-telangiectasia; and GTx-101, a topical spray for postherpetic neuralgia. The company’s target customer base consists of hospital healthcare systems, neurocritical intensive care units, healthcare providers, and patients suffering from rare conditions.
Company profile, executives and historyGrace Therapeutics stock: common questions
What is Grace Therapeutics's stock price?
GRCE closed at $1.85 on Nov 11, 2026, down 0.27% on the day. Over the past 52 weeks it traded between $1.67 and $5.18.
What is Grace Therapeutics's market cap?
Grace Therapeutics was worth $39.02M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is GRCE's P/E ratio?
Grace Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.18), so it has no meaningful P/E ratio.
Does Grace Therapeutics pay a dividend?
No. Grace Therapeutics has not paid a cash dividend over the last twelve months.
When does Grace Therapeutics report earnings next?
Grace Therapeutics is expected to report Q2 FY2027 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has GRCE stock performed over the past year?
Including dividends, GRCE returned -38.2% over the past year, against +12.4% for the S&P 500.
How many GRCE shares are sold short?
2M shares were sold short at the latest FINRA report, 12.74% of the float, or 12.3 days of average trading volume.
Who are Grace Therapeutics's competitors?
Companies most similar to Grace Therapeutics by business, industry and size include RCKT, SNGX, TNXP, MIRM, RKTO.
See a number that looks wrong?